Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

Immuno-Grade GPR32 Receptor Antibodies

Close filters
No results were found for the filter!
NEW
Immunohistochemical identification of GPR32 Receptor in Small Intestine
GPR32 (IHC-grade), G Protein-Coupled Receptor...
The GPR32 antibody is directed against the distal end of the carboxyl-terminal tail of mouse, rat and human GRP32. It can be used to detect total GPR32 receptors in Western blots independent of phosphorylation. The GPR32 antibody can...
$ 400.00 *
Details

GPR32 (G Protein-Coupled Receptor 32) is an orphan GPCR that has been identified as a receptor for specialized pro-resolving lipid mediators, particularly resolvin D1 (RvD1) and related D-series resolvins. These ligands are derived from omega-3 fatty acids and play a key role in the resolution of inflammation. GPR32 is expressed in various tissues, with notable expression in immune cells such as monocytes, macrophages, and neutrophils, as well as in vascular endothelial cells and some peripheral tissues. Its expression is closely linked to the regulation of immune and inflammatory responses. GPR32 is considered a promising pharmacological target for anti-inflammatory and pro-resolving therapies. Activation of GPR32 by resolvins has been shown to reduce inflammation, enhance clearance of apoptotic cells, and promote tissue repair. While selective agonists or modulators are still in development, GPR32 is being actively studied for potential therapeutic applications in chronic inflammatory diseases, cardiovascular conditions, and autoimmune disorders. For more information on GPR32 pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. PMID: 23686350; PMCID: PMC3698937.

Alexander SP, Battey J, Benson HE, Benya RV, Bonner TI, Davenport AP, Dhanachandra Singh K, Eguchi S, Harmar A, Holliday N, Jensen RT, Karnik S, Kostenis E, Liew WC, Monaghan AE, Mpamhanga C, Neubig R, Pawson AJ, Pin JP, Sharman JL, Spedding M, Spindel E, Stoddart L, Storjohann L, Thomas WG, Tirupula K, Vanderheyden P. Class A Orphans in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1). Available from: https://doi.org/10.2218/gtopdb/F16/2023.1.

GPR32 (G Protein-Coupled Receptor 32) is an orphan GPCR that has been identified as a receptor for specialized pro-resolving lipid mediators, particularly resolvin D1 (RvD1) and related D-series... read more »
Close window
Immuno-Grade GPR32 Receptor Antibodies

GPR32 (G Protein-Coupled Receptor 32) is an orphan GPCR that has been identified as a receptor for specialized pro-resolving lipid mediators, particularly resolvin D1 (RvD1) and related D-series resolvins. These ligands are derived from omega-3 fatty acids and play a key role in the resolution of inflammation. GPR32 is expressed in various tissues, with notable expression in immune cells such as monocytes, macrophages, and neutrophils, as well as in vascular endothelial cells and some peripheral tissues. Its expression is closely linked to the regulation of immune and inflammatory responses. GPR32 is considered a promising pharmacological target for anti-inflammatory and pro-resolving therapies. Activation of GPR32 by resolvins has been shown to reduce inflammation, enhance clearance of apoptotic cells, and promote tissue repair. While selective agonists or modulators are still in development, GPR32 is being actively studied for potential therapeutic applications in chronic inflammatory diseases, cardiovascular conditions, and autoimmune disorders. For more information on GPR32 pharmacology please refer to the IUPHAR database. For further reading refer to:

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ. International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands. Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. PMID: 23686350; PMCID: PMC3698937.

Alexander SP, Battey J, Benson HE, Benya RV, Bonner TI, Davenport AP, Dhanachandra Singh K, Eguchi S, Harmar A, Holliday N, Jensen RT, Karnik S, Kostenis E, Liew WC, Monaghan AE, Mpamhanga C, Neubig R, Pawson AJ, Pin JP, Sharman JL, Spedding M, Spindel E, Stoddart L, Storjohann L, Thomas WG, Tirupula K, Vanderheyden P. Class A Orphans in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE. 2023; 2023(1). Available from: https://doi.org/10.2218/gtopdb/F16/2023.1.

Recently viewed